Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Leask

Showing results (41-50 of 221) with videos related to

Pageof 23
Sort By:
Journal of Cell Communication and Signaling|April 13, 2011
CCN2: a bona fide target for anti-fibrotic drug interventionAndrew Leask
Journal of Cell Communication and Signaling|April 13, 2011
When there's smoke there's…scleroderma: evidence that patients with scleroderma should stop smokingAndrew Leask
Journal of Cell Communication and Signaling|March 17, 2012
CCN3: a novel anti-fibrotic treatment in end-stage renal disease?Andrew Leask
Methods in Molecular Biology (Clifton, N.J.)|October 14, 2016
CCN2 in Skin FibrosisAndrew Leask
Circulation Research|March 28, 2015
Getting to the heart of the matter: new insights into cardiac fibrosisAndrew Leask
Journal of Cell Communication and Signaling|July 25, 2020
Et tu, CCN1…Andrew Leask
Journal of Cell Communication and Signaling|May 20, 2021
Blisters on your fingersAndrew Leask
Journal of Cell Communication and Signaling|August 9, 2011
Sp1king out cancer (....and fibrosis?)Andrew Leask
Journal of Cell Communication and Signaling|March 30, 2022
Modeling the microenvironment special issueAndrew Leask
Pharmacological Research|February 15, 2011
The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosisAndrew Leask
Pageof 23

Showing results (41-50 of 221) with videos related to

Sort By:
Pageof 23
Journal of Cell Communication and Signaling|April 13, 2011
CCN2: a bona fide target for anti-fibrotic drug interventionAndrew Leask
Journal of Cell Communication and Signaling|April 13, 2011
When there's smoke there's…scleroderma: evidence that patients with scleroderma should stop smokingAndrew Leask
Journal of Cell Communication and Signaling|March 17, 2012
CCN3: a novel anti-fibrotic treatment in end-stage renal disease?Andrew Leask
Methods in Molecular Biology (Clifton, N.J.)|October 14, 2016
CCN2 in Skin FibrosisAndrew Leask
Circulation Research|March 28, 2015
Getting to the heart of the matter: new insights into cardiac fibrosisAndrew Leask
Journal of Cell Communication and Signaling|July 25, 2020
Et tu, CCN1…Andrew Leask
Journal of Cell Communication and Signaling|May 20, 2021
Blisters on your fingersAndrew Leask
Journal of Cell Communication and Signaling|August 9, 2011
Sp1king out cancer (....and fibrosis?)Andrew Leask
Journal of Cell Communication and Signaling|March 30, 2022
Modeling the microenvironment special issueAndrew Leask
Pharmacological Research|February 15, 2011
The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosisAndrew Leask
Pageof 23